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TO THE EDITORvon Willebrand Disease
After TAVR
The Missing Link?By abolishing the obstruction created by a highly
stenotic aortic valve, transcatheter aortic valve
replacement (TAVR) is an effective treatment for
severe aortic stenosis, with a hemodynamic proﬁle
(mean gradient and aortic valve area) at least similar
or even superior to conventional surgical aortic valve
replacement (1). However, the presence of para-
valvular leak (PVL) after TAVR has been shown to be
associated with increased mortality (2). Although a
negative impact on left ventricular recovery and
remodeling has been proposed as the primary causal
mechanism (3), the exact pathophysiology of PVL and
its association with increased mortality remains to be
completely understood.
Spangenberg et al. (4) elegantly demonstrated that
although TAVR was successful in resolving the
detrimental hematologic impact of aortic stenosis in
most patients, PVL was associated with a persistent
breakdown of high molecular weight von Willebrand
factor (vWF), suggesting an increase in ﬂow turbu-
lence. Although this ﬁnding is extremely interesting,
the low number of patients (N ¼ 95) included in their
study precludes any deﬁnitive conclusion regarding
the clinical implication of acquired vWF disease after
TAVR, both from a bleeding and mortality point of
view.
From a large cohort of 2,401 patients in the
randomized PARTNER (Placement of AoRTic TraNs-
cathetER Valve Trial), we recently demonstrated
that the strongest predictor of bleeding events be-
tween 30 days and 1 year after successful TAVR was
the presence of moderate to severe PVL (5). Although
some may argue that PVL may represent a marker of
patients’ sickness rather than a causal factor leading
to mortality, we suggested that signiﬁcant PVL, with
persistent increased ﬂow turbulence and shear stress,
may lead to the breakdown of the large molecular
weight vWF and consequently predispose patients to
late bleeding events, potentially contributing to
increased mortality.Whether high molecular weight vWF could be a
clinically useful surrogate marker of signiﬁcant PVL
(or any other states of high shear stress, such as
prosthesis-patient mismatch) in the future needs to
be investigated in a larger population; however, the
report of Spangenberg et al. (4), paired with our pre-
vious ﬁndings (5), suggests that vWF breakdown after
TAVR could be seen as the “missing link” among PVL,
late bleeding events, and its association with
increased mortality.*Philippe Généreux, MD
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The Missing Link?In reply to the letter of Dr. Généreux and colleagues,
we strongly agree with their continuative analysis
of our data that in conjunction with their work on
major late bleeding complications offer a substanti-
ated hypothesis for the paravalvular leakage (PVL)-
associated mortality after transcatheter aortic valve
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 9 , 2 0 1 5 Letters to the Editor
A U G U S T 1 7 , 2 0 1 5 : 1 2 6 6 – 7 6
1267replacement (TAVR). Furthermore, our study pro-
vides the asked for proof of the turbulence-induced
cleavage of proaggregation proteins (1) for the TAVR
population.
In summary, TAVR as well as surgical aortic valve
replacement lead to a resolution of high-molecular
weight multimer (HMW-MM) deﬁciency/acquired
von Willebrand-syndrome in patients with severe
aortic stenosis. However, PVL as well as prosthesis-
patient mismatch lead to persistent/recurrent factor
deﬁciency in the respective treatment modalities,
with severe (i.e., HMW-MM–deﬁcient) prosthesis-
patient mismatch appearing to occur more fre-
quently with surgical aortic valve replacement (2,3).
As of now and from a pathophysiological standpoint,
these ﬁndings fuel the thesis of PVL ultimately
translating into a HMW-MM-associated bleeding
diathesis and therefore increased mortality (4). But
this applies possibly even more so to patients with
atrial ﬁbrillation/atrial ﬂutter in need of oral anti-
coagulation or triple therapy after TAVR. Whether
HMW-MM/PVL status after TAVR should be incorpo-
rated into the post-procedural anticoagulant strategy
in order to reduce bleeding in this subset of patients,
reﬂecting up to 40% of the TAVR population, needs to
be clariﬁed by future studies.
Furthermore, with HMW-MM deﬁciency as an un-
derlying mechanism of PVL-associated mortality, ef-
forts to sidestep PVL-induced HMW-MM deﬁciency
are the logical primary consequence. Congruously,
HMW-MM reﬂected by platelet function analyzer-
closure time adenine DI-phosphate have just lately
been suggested to be capable of guiding these efforts
intraprocedural (5).
Deﬁnite evidence for the joint thesis thoughwill onlybe
available if future randomized trials reducing major late
bleeding complications demonstrate improved survival (1)
in a number of patients allowing deﬁnite conclusions.
With this in mind, consolidating the work of Généreux
et al. (4) providing bleeding-associated mortality as
driving force and target, ourwork indicating HMW-MM as
themissing link of bleeding associatedmortality and PVL,
and the work of Van Belle et al. (5) providing a technical
suggestion for intraprocedural HMW-MM-guided PVL
avoidance, ﬁnal clariﬁcation seems to be within reach.*Tobias Spangenberg, MD
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of Residual Atrial Septal
Defect Following
Transseptal Catheterization
for Intracardiac Interventional
ProceduresIatrogenic residual atrial septal defect (rASD)
following transseptal catheterization (TC) is a risk of
many interventional procedures. In a recent issue of
JACC: Cardiovascular Interventions, Schueler et al. (1)
reported a 50% rASD persistence rate after trans-
catheter mitral valve repair using the MitraClip sys-
tem (Abbott Vascular, Abbott Park, Illinois). The
assessment was made at 6-month transesophageal
echocardiography (TEE) follow-up. They concluded
that the persistent interatrial shunting was associated
with worse clinical outcomes and increased mortality.
However, there are some important deﬁciencies in
their methodology and data presentation that require
clariﬁcation.
The size of rASD and the time course for possible
regression are critical parameters that will affect clin-
ical hemodynamic and cardiac function. Previous
studies using Mullins TC sheath (Medtronic,
